Venture funding rises in 2Q; NGM, Audentes and Lithera grab 3Q deals
This article was originally published in Scrip
Venture capital funding for US health care companies ramped up in the second quarter of 2013 after several quarters of decline compared to year-ago levels, and recent deals show significant venture dealmaking for biotechnology companies to kick off the third quarter of this year.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.